> Clinical trials to date
> Initial publication -Phlebology
> Management of foot and leg ulcers
> A randomised controlled trial: Kerraboot vs Allevyn^®
> Kerraboot – benefits of treatment
> Beyond lower limb ulcers:
> surgical debridement and skin grafting
> Case studies

Management of foot and leg ulcers
Leigh R, Barker SGE, Murray N, Hurel SJ. The Kerraboot: A novel wound dressing device for the management of leg and foot ulcers. Practical Diabetes International 2004;21:27-30.

Another new trial was then undertaken using the new version of Kerraboot in diabetic patients with neuropathic, neuroischaemic or arterial ulcers on the foot or lower leg. Boot changes were once per day, or once every other day, for a maximum 28-day period. Patients completed a questionnaire to assess comfort, acceptability, mobility, security and convenience. Healthcare staff assessed ease of management.

This study demonstrated the overall utility of Kerraboot in the management of leg ulcers. Patients found Kerraboot comfortable and very convenient to wear. Over the study period all ulcers reduced in size: 82% by up to 50% and 18% by over 50%. Ulcer related odour was virtually eliminated. Of the patients asked, all reported Kerraboot to be ‘convenient’ and ‘secure’, and reported that Kerraboot was ‘better’ or ‘much better’ than previously used dressings. Healthcare staff confirmed the ease of application and removal and most rated Kerraboot as better than any dressings previously used. Diabetic neuropathic and neuroischaemic ulcers showed a marked reduction in size during the study and 2 patients with neuropathic ulcers were sufficiently clean and granulating to have skin grafts.



Back to the top